T
Taroh Satoh
Researcher at Kindai University
Publications - 122
Citations - 8983
Taroh Satoh is an academic researcher from Kindai University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 71 publications receiving 7800 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka,Kreshnik Zejnullahu,Isamu Okamoto,Taroh Satoh,Federico Cappuzzo,John Souglakos,Dalia Ercan,Andrew H. Rogers,Massimo Roncalli,Masayuki Takeda,Yasuhito Fujisaka,Juliet Philips,Toshio Shimizu,Osamu Maenishi,Yonggon Cho,Jason Sun,Annarita Destro,Koichi Taira,Koji Takeda,Takafumi Okabe,Jeffrey Swanson,Hiroyuki Itoh,Minoru Takada,Eugene Lifshits,Kiyotaka Okuno,Jeffrey A. Engelman,Ramesh A. Shivdasani,Ramesh A. Shivdasani,Kazuto Nishio,Masahiro Fukuoka,Marileila Varella-Garcia,Kazuhiko Nakagawa,Pasi A. Jänne,Pasi A. Jänne +33 more
TL;DR: Examination of cellular data with patient experience improves confidence that concomitant treatment of certain lung, head and neck, or colorectal cancers with cetuximab and an anti-ERBB2 drug may prevent or delay the development of drug resistance.
Journal ArticleDOI
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
Taroh Satoh,Rui-Hua Xu,Hyun Cheol Chung,Guo-ping Sun,Toshihiko Doi,Jianming Xu,Akihito Tsuji,Yasushi Omuro,Jin Li,Jinwan Wang,Hiroto Miwa,Shukui Qin,Ik-Joo Chung,Kun-Huei Yeh,Jifeng Feng,Akihira Mukaiyama,Mikiro Kobayashi,Atsushi Ohtsu,Yung-Jue Bang +18 more
TL;DR: Lapatinib plus paclitaxel demonstrated activity in the second-line treatment of patients with HER2 FISH-positive IHC3+ advanced gastric cancer but did not significantly improve OS in the intent-to-treat population.
Journal ArticleDOI
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
Kenji Tamura,Isamu Okamoto,Tatsuhiko Kashii,S. Negoro,T. Hirashima,S. Kudoh,Yukito Ichinose,N Ebi,K Shibata,Toshihide Nishimura,Nobuyuki Katakami,T Sawa,Eiji Shimizu,Junya Fukuoka,Taroh Satoh,Masahiro Fukuoka +15 more
TL;DR: Gefitinib chemotherapy in patients with advanced NSCLC harbouring EGFR mutations was highly effective, demonstrating the benefit to patients of selecting gefit inib treatment based on their EGFR mutation status.
Journal ArticleDOI
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro,Narikazu Boku,Yasuhiro Shimada,Akihito Tsuji,Shinichi Sameshima,Hideo Baba,Taroh Satoh,Tadamichi Denda,Kenji Ina,Tomohiro Nishina,Kensei Yamaguchi,Hiroya Takiuchi,Taito Esaki,Shinya Tokunaga,Hiroyuki Kuwano,Yoshito Komatsu,Masahiko Watanabe,Ichinosuke Hyodo,Satoshi Morita,Kenichi Sugihara +19 more
TL;DR: Progression-free survival with IRIS is not inferior to that with FOLFIRI in patients receiving second-line chemotherapy for metastatic colorectal cancer.